Evidence mapPaperPMID 40326310Full record

SynthesisEmerging microbes & infections2025

New onset of type 1 and type 2 diabetes post-COVID-19 infection: a systematic review.

Ahmed El-Naas, Omar Hamad, Siddhant Nair, Bushra Alfakhri, Shadi Mahmoud, Aliyaa Haji, Lina Ahmed, Ahamed Lebbe, Ali Aboulwafa, Farha Shaikh and 2 more

Abstract readSystematic Review
In one paragraph

Synthesis in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ahmed El-NaasDepartment of Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar.
Omar HamadDepartment of Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar.
Siddhant NairDepartment of Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar.
Bushra AlfakhriDepartment of Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar.
Shadi MahmoudDepartment of Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar.
Aliyaa HajiDepartment of Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar.
Lina AhmedDepartment of Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar.
Ahamed LebbeDepartment of Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar.
Ali AboulwafaDepartment of Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar.
Farha ShaikhDepartment of Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar.
Imane BouhaliDepartment of Medical Education, Weill Cornell Medicine-Qatar, Doha, Qatar.
Dalia ZakariaDepartment of Premedical Education, Weill Cornell Medicine-Qatar, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 may primarily cause respiratory symptoms but can lead to long-term effects known as long COVID. COVID-19-induced diabetes mellitus was reported in many patients which shares characteristics of types 1 and 2 (T1DM and T2DM). This study aims to identify and analyse the reported cases of new onset diabetes post-COVID-19 infection. Several databases were used to conduct a comprehensive literature search to target studies reporting cases of T1DM or T2DM post-COVID-19 infection. Screening, data extraction, and cross-checking were performed by two independent reviewers. Only 43 studies met our inclusion criteria. Our results revealed that the overall prevalence of new onset diabetes post-COVID-19 was 1.37% with higher prevalence for T2DM (0.84%) as compared to T1DM (0.017%) while the type of diabetes was not reported in 0.51% of the cases. Several risk factors for developing diabetes post-COVID-19 infection were identified including the type of SARS-CoV-2 variant, age, comorbidities, and the vaccination status. The direct viral attack of the pancreatic beta cells as well as inflammation and the anti-inflammatory corticosteroids were proposed as possible mechanisms of the COVID-19 induced diabetes. A multidisciplinary approach involving endocrinologists, primary care physicians, and infectious disease specialists should be implemented in the management of post-COVID patients to address both the acute and long-term complications, including metabolic changes and risk of diabetes.

Indexed as

COVID-19Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansPrevalenceRisk FactorsSARS-CoV-2COVID-19diabetes“Post-COVID sequelae”SARS-CoV-2type 1 diabetestype 2 diabetes

Identifiers

PMID40326310
PMCPMC12261520

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.